Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
| Revenue (TTM) | $22.48B |
| Gross Profit (TTM) | $10.55B |
| EBITDA | $6.12B |
| Operating Margin | 15.70% |
| Return on Equity | 6.61% |
| Return on Assets | 4.34% |
| Revenue/Share (TTM) | $79.76 |
| Book Value | $89.64 |
| Price-to-Book | 2.09 |
| Price-to-Sales (TTM) | 2.24 |
| EV/Revenue | 2.989 |
| EV/EBITDA | 13.66 |
| Quarterly Earnings Growth (YoY) | -31.40% |
| Quarterly Revenue Growth (YoY) | 5.40% |
| Shares Outstanding | $272.39M |
| Float | $271.67M |
| % Insiders | 0.43% |
| % Institutions | 99.78% |
Volatility is currently contracting
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns.
On a recent edition of CNBC's Mad Money Lightning Round, Jim Cramer fielded questions from viewers. Two of Cramer's clearest calls were to buy Vale (NYSE:VALE | VALE Price Prediction) as an inflation hedge comparable to cryptocurrency and to stay long Apple (NASDAQ:AAPL) through an upcoming leadership change.
STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture.
FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m.
BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.
FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.
Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.
Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.
About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BDX and any ticker you trade — then tracks every position and per-strategy win rate.
